Publications
Publications
Jun, 2025
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
We are excited to share that our latest
manuscript, "Real-world outcomes
of duvelisib and romidepsin combination
therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL),"
has been accepted for publication in
Blood Advances. Read more on how it
offers critical real-world
evidence supporting a promising
treatment strategy to improve
outcomes and facilitate curative
transplants for patients with
aggressive PTCL.
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
May, 2025
We are excited to announce that our paper, Forecasting optimal treatments
in relapsed/refractory mature T- and NK-cell lymphomas, has been
published in the British Journal of Haematology. This collaborative work
leverages machine learning and genomic insights to predict the most
effective treatment regimens for aggressive T- and NK-cell lymphomas.
We are excited to announce that
our paper, Forecasting optimal treatments
in relapsed/refractory mature T-
and NK-cell lymphomas, has been
published in the British Journal of
Haematology. This collaborative work
leverages machine learning and genomic
insights to predict the most
effective treatment regimens for
aggressive T- and NK-cell lymphomas.
We are excited to announce that our paper, Forecasting optimal treatments
in relapsed/refractory mature T- and NK-cell lymphomas, has been
published in the British Journal of Haematology. This collaborative work
leverages machine learning and genomic insights to predict the most
effective treatment regimens for aggressive T- and NK-cell lymphomas.
October, 2024
Another great milestone achieved for PETAL as our paper, “Global Outcomes and Prognosis for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas: Results from the PETAL Consortium,” has been accepted for publication in Blood Advances, the open-access journal of the American Society of Hematology.
Another great milestone achieved
for PETAL as our paper,
“Global Outcomes and Prognosis
for Relapsed/Refractory Mature
T-Cell and NK-Cell Lymphomas:
Results from the PETAL
Consortium,”
has been accepted for publication
in Blood Advances, the
open-access journal of the
American Society of Hematology.
Another great milestone achieved for PETAL as our paper, “Global Outcomes and
Prognosis for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas:
Results from the PETAL Consortium,” has been accepted for publication in Blood
Advances, the open-access journal of the American Society of Hematology.
@2025 PETAL Consortium • All rights reserved
@2025 PETAL Consortium • All rights reserved
@2025 PETAL Consortium • All rights reserved